Salivary gland carcinoma
MONDO:0000521A carcinoma that arises from the major or minor salivary glands. Representative examples include carcinoma ex pleomorphic adenoma, adenocarcinoma, adenoid cystic carcinoma, and mucoepidermoid carcinoma.
Also known as: salivary gland cancer, carcinoma of saliva-secreting gland, carcinoma of salivary gland, carcinoma of the salivary gland, saliva-secreting gland carcinoma, salivary gland carcinoma, salivary carcinoma
2998 clinical trials for this condition and its sub-types, 26 tagged with Salivary gland carcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Salivary gland carcinoma
-
Major salivary gland carcinoma 6 trials
6 sub-types
- Carcinoma of parotid gland 0 trials Sub-types →
- Major salivary gland adenoid cystic carcinoma 0 trials Sub-types →
- Major salivary gland carcinoma ex pleomorphic adenoma 0 trials Sub-types →
- Major salivary gland mucoepidermoid carcinoma 0 trials Sub-types →
- Sublingual gland carcinoma 0 trials Sub-types →
- Submandibular gland cancer 0 trials Sub-types →
-
2 sub-types
- Parotid gland squamous cell carcinoma 0 trials
- Salivary gland adenosquamous carcinoma 0 trials
-
Salivary duct carcinoma 3 trials
-
2 sub-types
-
Mammary analog secretory carcinoma 0 trials
-
Minor salivary gland carcinoma 0 trials
1 sub-type
-
1 sub-type
-
Salivary gland large cell carcinoma 0 trials
-
1 sub-type
-
Salivary gland small cell carcinoma 0 trials
Most studied deeper sub-types
-
New pill-chemo combo takes on hard-to-treat cancers
Disease control Not yet recruitingThis study tests a new drug called SX-682 (a tablet) combined with the chemotherapy docetaxel in people whose head/neck, salivary gland, or prostate cancer has spread or returned after treatment. The goal is to find the right dose and see if the combination shrinks tumors. About …
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 21, 2026 22:00 UTC
-
New combo therapy takes aim at Hard-to-Treat salivary gland cancer
Disease control Not yet recruitingThis phase II trial tests a combination of an antibody-drug conjugate (a targeted cancer drug) and stereotactic body radiotherapy (precise, high-dose radiation) in 40 people with recurrent or metastatic salivary gland cancer. Participants first receive the drug; if their disease …
Phase 2 • Sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC